Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – “The deal, however, only covers 53 percent of the world’s population and excludes people in several upper-middle-income countries, leaving this promising medicine out of reach for millions”.

17 Nov, 2021 | 08:38h | UTC

MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – Médecins Sans Frontières

 

Commentary on Twitter

 

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

17 Nov, 2021 | 08:42h | UTC

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians – The Journal of the American Board of Family Medicine

Related:

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome.

16 Nov, 2021 | 08:48h | UTC

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

IDSA/ASM Consensus Review Document: Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping.

16 Nov, 2021 | 08:50h | UTC

Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: An IDSA/ASM Consensus Review Document – Clinical Infectious Diseases

News Release: New review article outlines potential of SARS-CoV-2 genetic sequencing in patient care – American Society for Microbiology

 

Review: Vaccine-induced immune thrombotic thrombocytopenia.

16 Nov, 2021 | 08:46h | UTC

Vaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology

Related:

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

 

Covid: Austria introduces lockdown for unvaccinated.

16 Nov, 2021 | 08:43h | UTC

Covid: Austria introduces lockdown for unvaccinated – BBC

See also: Austria orders nationwide lockdown for the unvaccinated – Associated Press

 

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding.

16 Nov, 2021 | 08:42h | UTC

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding – The BMJ

 

Commentary on Twitter

 

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more.

16 Nov, 2021 | 08:41h | UTC

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used.

16 Nov, 2021 | 08:39h | UTC

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

[Preprint] Risk of severe COVID-19 is rare among fully vaccinated individuals in England.

14 Nov, 2021 | 20:10h | UTC

Commentary: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical

Original Study: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv

 

Phase 4 RCT: Concomitant administration of COVID-19 vaccines (AstraZeneca or Pfizer) with seasonal influenza vaccines in adults is safe and preserves antibody responses to both vaccines.

14 Nov, 2021 | 20:14h | UTC

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

 

Large populational study finds prior SARS-CoV-2 infection reduces the risk of breakthrough infection following mRNA vaccination.

14 Nov, 2021 | 20:12h | UTC

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Commentaries:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Commentary on Twitter

 

Populational study in Qatar showed the effectiveness against SARS-CoV-2 Delta-induced severe, critical or fatal disease was 93.4% for the Pfizer vaccine and 96.1% for Moderna.

14 Nov, 2021 | 20:11h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Commentary on Twitter

 

What influences people’s responses to public health messages for managing risks and preventing infectious diseases? A rapid systematic review of the evidence and recommendations.

14 Nov, 2021 | 20:06h | UTC

What influences people’s responses to public health messages for managing risks and preventing infectious diseases? A rapid systematic review of the evidence and recommendations – BMJ Open

 

Commentary on Twitter

 

SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study.

14 Nov, 2021 | 20:05h | UTC

News Release: SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study – Harvard Medical School

Original study: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study – Journal of Clinical Oncology

 

Commentary from the author on Twitter (thread – click for more)

 

#AHA21 – RCT: Among children and adolescents who had screening echocardiograms and were identified as having latent rheumatic heart disease, secondary antibiotic prophylaxis with penicillin G benzathine for 2 years was associated with reduced echocardiographic progression (0.8 vs. 8.2% in the control group).

14 Nov, 2021 | 20:03h | UTC

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Penicillin significantly reduces rheumatic heart disease progression in children – Murdoch Children’s Research Institute

Penicillin slows devastating impacts of rheumatic heart disease in children from Uganda – Children’s National Hospital

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – American College of Cardiology

 

Commentaries on Twitter

 

Editorial: COVID is disrupting scientific careers around the world.

14 Nov, 2021 | 20:08h | UTC

COVID is disrupting scientific careers around the world – Nature

See also:

Scientists count the career costs of COVID – Nature

Potentially long-lasting effects of the pandemic on scientists – Nature

 

RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults.

12 Nov, 2021 | 10:43h | UTC

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet

Invited Commentary: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet

Related: WHO issues emergency use approval for India’s Covaxin.

 

Commentary on Twitter

 

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

12 Nov, 2021 | 10:39h | UTC

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – Nature

Related:

[Preprint] Study confirms children’s extremely low risk of death from Covid-19 – “99·995% of children and young people with a positive SARS-CoV-2 test survived”.

Study: Children and young people remain at low risk of COVID-19 mortality

 

Commentaries on Twitter

 

Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method.

12 Nov, 2021 | 10:41h | UTC

Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method – The Lancet Infectious Diseases

 

Commentary from the author on Twitter (thread – click for more)

 

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

12 Nov, 2021 | 10:32h | UTC

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID – The Lancet

Related:

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

Boosting immunity to COVID-19 vaccines – “New studies highlight the immunological benefits of COVID-19 vaccine boosters, but questions remain over how to best make use of a limited global supply”.

12 Nov, 2021 | 10:37h | UTC

Boosting immunity to COVID-19 vaccines – Nature Medicine

 

Map: The world according to covid vaccine coverage.

12 Nov, 2021 | 10:34h | UTC

The world according to covid vaccine coverage – The BMJ

 

Commentary on Twitter

 

WHO, CDC | Global progress against measles threatened amidst COVID-19 pandemic.

12 Nov, 2021 | 10:27h | UTC

News Release: Global progress against measles threatened amidst COVID-19 pandemic – World Health Organization

Report: Progress Toward Regional Measles Elimination — Worldwide, 2000–2020 – CDC Morbidity and Mortality Weekly Report

Commentary: Measles is a renewed global threat after 22 million babies missed their vaccines during the pandemic, CDC warns – CNN

 

Commentary on Twitter (thread – click for more)

 

Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis – “Each day of antibiotic therapy was associated with 4% increased odds of experiencing an adverse event”.

12 Nov, 2021 | 09:47h | UTC

Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis – Clinical Microbiology and Infection

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.